RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi

• Verfasst von: Helmbold, Peter [VerfasserIn]
• Verfasst von: Skorokhod, Alexander [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Titel: RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi
• Verf.angabe: Peter Helmbold, Antje M. Richter, Sara Walesch, Alexander Skorokhod, Wolfgang Ch. Marsch, Alexander Enk and Reinhard H. Dammann
• E-Jahr: 2012
• Jahr: March 2012
• Umfang: 8 S.
• Fussnoten: Online veröffentlicht: 24. November 2011 ; Gesehen am 26.04.2018
• Titel Quelle: Enthalten in: The journal of investigative dermatology
• Ort Quelle: Amsterdam : Elsevier, 1938
• Jahr Quelle: 2012
• Band/Heft Quelle: 132(2012), 3, Part 1, Seite 687-694
• ISSN Quelle: 1523-1747
• DOI: doi:10.1038/jid.2011.380
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1572417234

Abstract

The Ras association domain family (RASSF) consists of several tumor suppressor genes, which are frequently silenced in human cancers. We analyzed the epigenetic inactivation of RASSF2 and RASSF10 in malignant melanoma (MM) of the skin, including 5 MM cell lines, 28 primary MM, 33 metastases of MM, 47 nevus cell nevi (NCN), and 22 control tissues. The RASSF2 promoter was epigenetically downregulated in two MM cell lines only, but not in any of the investigated tumor samples. In contrast, hypermethylation of the RASSF10 promoter was found in all investigated cell lines, 19/28 (68%) of the primary MM and 30/33 (91%) of the MM metastases, 2/18 (11%) of the dysplastic NCN, and 0/29 (0%) of the non-dysplastic NCN (difference between MM and all nevi, P<0.001). RASSF10 promoter hypermethylation correlated with a reduced RASSF10 mRNA expression in 3/4 MM cell lines, and treatment with a DNA methylation inhibitor reactivated RASSF10 transcription. Furthermore, immunohistological RASSF10 expression corresponds negatively to its promoter methylation state. In summary, RASSF10 proved to be a characteristically epigenetically silenced tumor suppressor in melanomagenesis, and analysis of RASSF10 methylation status represents a new candidate tool to assist in discrimination between MM and NCN.